Avant Technologies Inc., a leading Nevada-based corporation and SGAustria Pte. Ltd., a known Singapore biotechnology company, have formed a groundbreaking alliance and signed a license agreement to bring revolutionary positive changes and advancement in diabetes treatment via encapsulation technologies and innovative stem cells. Further heading the joint venture will make a Research Collaboration Agreement (RCA) to enhance an exclusive differentiation process that potentially covert stem cells into regulating and insulin-producing cells.
This builds the core of the therapy for a few insulin-dependent type 2 and type 1 diabetes patients. This partnership aims to market, produce, and research valuable diabetes treatments that incorporate encapsulated stem cells-differentiated prior to, after and during encapsulation. By unifying capable RCA translated stem cell expertise with SGAustria’s encapsulation platform, both partners will help to serve potent, scalable and safe solutions for a few insulin-dependent type 2 and type 1 diabetes patients worldwide.
The Chief Executive Officer at Avant’s, Chris Winter, said, “We’re excited to be a part of the SGAustria journey, sailing on this joint venture ship. Consolidating our forward thinking and capital with their sophisticated biotech innovations, we’re creating a space for revolutionary diabetes therapies that can transform infinite lives. This profit shows a definitive step for Avant as we’re dedicated to serving the best to the advancement of regenerative healthcare.”
SGAustria brings clinically proven, exclusive cell-encapsulation technology, engineered to safeguard, transport, store and isolate living cells. The technology is supported by above 50 peer-reviewed contracts and publications with popular global biotechnology companies. SGAustria’s expertise in GMP-grade manufacturing and cell biology will contribute to the commercialisation and development of these treatments.
Whereas, Avant Technologies will provide primary funding in the next eight months to accomplish as developed criteria considered for a reproducible, sustainable and efficient treatment of diabetes. Alongside, Avant will accelerate its resources to lock the upcoming funding raised to enhance the joint venture towards an excellent phase 1 clinical trial in the US or other territories accordingly.
The CEO of SGAustria, Brian Salmons, said, “SGAustria’s encapsulation platform commits to reframing the cell therapies, and this joint venture is evidence of the potential. Merging with prospective partner RCA and Avant enables us to accelerate our joint potential to serve reliable, sophisticated treatments backed by our developed proficiency in cellular science and GMP production.”
Holding M.Pharm in Pharmaceutical Chemistry, Chandni crafts cutting-edge, research-driven healthcare news for Towards Healthcare, combining scientific depth with innovative storytelling to simplify complex topics for global readers.
